Cargando…

Engineering pH responsive fibronectin domains for biomedical applications

BACKGROUND: Engineered antibodies with pH responsive cell surface target antigen-binding affinities that decrease at the acidic pH (5.5-5.8) within the endosomes have been found to have reduced susceptibility to degradation within the lysosomes and increased serum half-life. Such pH responsive recom...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzelman, Pete, Krais, John, Ruben, Eliza, Pantazes, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477602/
https://www.ncbi.nlm.nih.gov/pubmed/26106447
http://dx.doi.org/10.1186/s13036-015-0004-1
_version_ 1782377780475854848
author Heinzelman, Pete
Krais, John
Ruben, Eliza
Pantazes, Robert
author_facet Heinzelman, Pete
Krais, John
Ruben, Eliza
Pantazes, Robert
author_sort Heinzelman, Pete
collection PubMed
description BACKGROUND: Engineered antibodies with pH responsive cell surface target antigen-binding affinities that decrease at the acidic pH (5.5-5.8) within the endosomes have been found to have reduced susceptibility to degradation within the lysosomes and increased serum half-life. Such pH responsive recombinant antibodies have been developed for the treatment of cancer and cardiovascular disease. Engineered tenth type III human fibronectin (Fn3) domains are emerging as a class of target antigen-binding biopharmaceuticals that could complement or be superior to recombinant antibodies in a number of biomedical contexts. As such, there is strong motivation for demonstrating the feasibility of engineering Fn3s with pH responsive antigen binding behavior that could lead to improved Fn3 pharmacokinetics. RESULTS: A yeast surface-displayed Fn3 histidine (His) mutant library screening approach yielded epidermal growth factor receptor (EGFR)-binding Fn3 domains with EGFR binding affinities that markedly decrease at endosomal pH; the first reported case of engineering Fn3s with pH responsive antigen binding. Yeast surface-displayed His mutant Fn3s, which contain either one or two His mutations, have equilibrium binding dissociation constants (K(D)s) that increase up to four-fold relative to wild type when pH is decreased from 7.4 to 5.5. Assays in which Fn3-displaying yeast were incubated with soluble EGFR after ligand-free incubation in respective neutral and acidic buffers showed that His mutant Fn3 pH responsiveness is due to reversible changes in Fn3 conformation and/or EGFR binding interface properties rather than irreversible unfolding. CONCLUSIONS: We have established a generalizable method for efficiently constructing and screening Fn3 His mutant libraries that could enable both our laboratory and others to develop pH responsive Fn3s for use in a wide range of biomedical applications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13036-015-0004-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4477602
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44776022015-06-24 Engineering pH responsive fibronectin domains for biomedical applications Heinzelman, Pete Krais, John Ruben, Eliza Pantazes, Robert J Biol Eng Research BACKGROUND: Engineered antibodies with pH responsive cell surface target antigen-binding affinities that decrease at the acidic pH (5.5-5.8) within the endosomes have been found to have reduced susceptibility to degradation within the lysosomes and increased serum half-life. Such pH responsive recombinant antibodies have been developed for the treatment of cancer and cardiovascular disease. Engineered tenth type III human fibronectin (Fn3) domains are emerging as a class of target antigen-binding biopharmaceuticals that could complement or be superior to recombinant antibodies in a number of biomedical contexts. As such, there is strong motivation for demonstrating the feasibility of engineering Fn3s with pH responsive antigen binding behavior that could lead to improved Fn3 pharmacokinetics. RESULTS: A yeast surface-displayed Fn3 histidine (His) mutant library screening approach yielded epidermal growth factor receptor (EGFR)-binding Fn3 domains with EGFR binding affinities that markedly decrease at endosomal pH; the first reported case of engineering Fn3s with pH responsive antigen binding. Yeast surface-displayed His mutant Fn3s, which contain either one or two His mutations, have equilibrium binding dissociation constants (K(D)s) that increase up to four-fold relative to wild type when pH is decreased from 7.4 to 5.5. Assays in which Fn3-displaying yeast were incubated with soluble EGFR after ligand-free incubation in respective neutral and acidic buffers showed that His mutant Fn3 pH responsiveness is due to reversible changes in Fn3 conformation and/or EGFR binding interface properties rather than irreversible unfolding. CONCLUSIONS: We have established a generalizable method for efficiently constructing and screening Fn3 His mutant libraries that could enable both our laboratory and others to develop pH responsive Fn3s for use in a wide range of biomedical applications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13036-015-0004-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-15 /pmc/articles/PMC4477602/ /pubmed/26106447 http://dx.doi.org/10.1186/s13036-015-0004-1 Text en © Heinzelman et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Heinzelman, Pete
Krais, John
Ruben, Eliza
Pantazes, Robert
Engineering pH responsive fibronectin domains for biomedical applications
title Engineering pH responsive fibronectin domains for biomedical applications
title_full Engineering pH responsive fibronectin domains for biomedical applications
title_fullStr Engineering pH responsive fibronectin domains for biomedical applications
title_full_unstemmed Engineering pH responsive fibronectin domains for biomedical applications
title_short Engineering pH responsive fibronectin domains for biomedical applications
title_sort engineering ph responsive fibronectin domains for biomedical applications
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477602/
https://www.ncbi.nlm.nih.gov/pubmed/26106447
http://dx.doi.org/10.1186/s13036-015-0004-1
work_keys_str_mv AT heinzelmanpete engineeringphresponsivefibronectindomainsforbiomedicalapplications
AT kraisjohn engineeringphresponsivefibronectindomainsforbiomedicalapplications
AT rubeneliza engineeringphresponsivefibronectindomainsforbiomedicalapplications
AT pantazesrobert engineeringphresponsivefibronectindomainsforbiomedicalapplications